A Novel Unadjuvanted Subunit Respiratory Syncytial Virus Prefusion F Vaccine Induces Potent and Differentiated Functional Immune Responses Compared to AS01-Adjuvanted Arexvy in Older Adults

In older adults, SCB-1019T had an acceptable and favorable safety profile. The humoral immunogenicity SCB-1019T was similar to that of Arexvy, which contains the potent AS01_E adjuvant. Therefore, this phase 1 study supports further development of SCB-1019T, notably in heterologous booster settings.